Wedbush Equities Analysts Raise Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a note issued to investors on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.57) per share for the quarter, up from their previous estimate of ($0.58). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($2.01) EPS.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

A number of other brokerages have also commented on STOK. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $8.15 on Friday. Stoke Therapeutics has a one year low of $6.29 and a one year high of $17.58. The company has a market cap of $431.68 million, a PE ratio of -3.88 and a beta of 0.99. The firm has a 50-day moving average of $9.47 and a 200-day moving average of $11.42.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC purchased a new position in Stoke Therapeutics during the 3rd quarter valued at about $160,000. Charles Schwab Investment Management Inc. boosted its position in shares of Stoke Therapeutics by 9.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock valued at $3,885,000 after acquiring an additional 26,870 shares during the period. BNP Paribas Financial Markets grew its stake in Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after acquiring an additional 71,647 shares in the last quarter. Checkpoint Capital L.P. bought a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $1,936,000. Finally, RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares in the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 in the last quarter. 11.30% of the stock is currently owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.